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Abstract
The current in vivo models for the utility and discovery of new potential anti-leishmanial
drugs targeting Cutaneous Leishmaniasis (CL) differ vastly in their immunological re-
sponses to the disease and clinical presentation of symptoms. Animal models that show
similarities to the human form of CL after infection with Leishmania should be more repre-
sentative as to the effect of the parasite within a human. Thus, these models are used to
evaluate the efficacy of new anti-leishmanial compounds before human clinical trials.
Current animal models aim to investigate (i) host–parasite interactions, (ii) pathogenesis,
(iii) biochemical changes/pathways, (iv) in vivo maintenance of parasites, and (v) clinical
evaluation of drug candidates. This review focuses on the trends of infection observed
between Leishmania parasites, the predictability of different strains, and the determination
of parasite load. These factors were used to investigate the overall effectiveness of the cur-
rent animal models. The main aim was to assess the efficacy and limitations of the various
CL models and their potential for drug discovery and evaluation. In conclusion, we found
that the following models are the most suitable for the assessment of anti-leishmanial drugs:
L.major–C57BL/6 mice (or–vervet monkey, or–rhesus monkeys), L. tropica–CsS-16mice,
L. amazonensis–CBAmice, L. braziliensis–golden hamster (or–rhesus monkey). We also pro-
vide in-depth guidance for which models are not suitable for these investigations.
Introduction
Cutaneous Leishmaniasis (CL) is a poverty-associated disease that presents as lesions in the
form of ulcers, nodules, papules, and plaques on exposed body parts (arms, legs, face). There
are approximately 1 million new cases of CL each year; however, it is difficult to estimate the
true incidence of leishmaniasis due to a lack of surveillance systems in remote areas and mar-
ginalized populations where the disease occurs, and because it is not a reportable disease within
the health systems of many endemic countries. CL has a wide geographical range, with the
majority of cases occurring in Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia,
Sudan, Costa Rica, and Peru. It is estimated that there are 20 species of Leishmania that cause
CL, each with different epidemiology and natural history. Some species of Leishmania are
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more common than others, and their incidences vary widely amongst their geographical loca-
tions. The most common Old World species that cause CL are L. tropica, L. aethiopica, and L.
major and the NewWorld parasites include L.mexicana, L. amazonensis, L. braziliensis, L.
panamensis, and L. guyanensis [1]. It must be noted that hybrid Leishmania have been isolated
in nature and conjugation (transfer of genetic materials) has been demonstrated in the sandfly
vector [2].
Leishmania infections typically originate from the bite of sandflies belonging to either Phle-
botomus spp (Old World) or Lutzomyia spp (NewWorld), which transmit the parasites into
the skin of the host. The first sign of infection appears as a small erythema that develops at the
site of the sandfly bite and advances within a few weeks to months. Lesions often become
chronic after the initial erythema develops into a papule, then a nodule that may ulcerate over
a period of two weeks to six months before becoming the characteristic lesion [3]. In strict CL,
each lesion is representative of an independent fly bite, but, in rare cases, the disease can mani-
fest as a disseminated disease (diffuse CL [DCL]) [4].
There is currently no satisfactory treatment for any form of CL and a need to develop short,
safe, efficacious, affordable, and field-friendly treatments for the disease. The Drugs for
Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, nonprofit drug
research and development (R&D) organization that is developing new treatments for neglected
diseases, including drug discovery against CL. DNDi decided to focus on development of treat-
ment for CL that is predominately caused by the L. tropica and L. braziliensis species. This is
due to the severity and public health importance of these particular species; however, it is likely
that these new treatments would be efficacious against CL caused by other parasites, too, as
described in the 2007 consultative meeting to develop a strategy for treatment of cutaneous
leishmaniasis [5]. Here, they suggest that these parasites will be targeted primarily because of
the public health importance of the disease they produce. L. tropica is an anthroponotic para-
site; therefore, treatment of cases is essential for controlling transmission. L. braziliensis is asso-
ciated with mucosal leishmaniasis (ML) more often than other NewWorld Leishmania, and
one risk factor for developing ML is duration of infection. Hence, again, early treatment is
important for control of ML. Furthermore, it was suggested that highly active drugs against
L. tropica and L. braziliensismay be active against others (such as amphotericin-B). Decisions
on how to treat CL are individualized. Treatment approach depends on a number of factors,
including Leishmania spp. and/or geographic incidence as well as clinical characteristics and
symptoms. For example, the oral agent miltefosine has FDA-approved indications that are lim-
ited to L. braziliensis, L. panamensis, and L. guyanensis.
Animal models can be used to evaluate drug candidates, with the goal of developing new
drugs that offer a safe, effective, and shorter-course treatment for CL, as well as an acceptable
safety profile. Therefore, it is essential to review the current animal models, which are highly
diverse, and provide guidance on which models are the best for the discovery and utility of new
anti-leishmanial drugs.
Animal Models for Different Species of Leishmania
It must be noted that there is no validated animal model for CL, although these models are rou-
tinely used in several laboratories. Animal model validity refers to the similarity between the
model and the human condition. Standardized animal models are used in laboratories that
screen drug compounds against Leishmania strains to assure reproducibility. However, the pre-
dictive validity of the animal models is often low due to incomplete correlation between animal
and human disease mechanisms. The philosophy is that if an agent was ineffective in these
models, then no further development would be justified. Besides, some preliminary data on
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dose response and toxicity may be collected. Certain parameters must be considered when
determining the similarity of an animal model to the human disease. These parameters include,
but are not limited to, the clinical manifestations and presentations of the disease, disease path-
ogenesis, and the immunological responses that occur. For an animal model to be considered
“validated” and used as part of preclinical development studies of an agent for therapy or pro-
phylaxis, it must be similar to humans with respect to etiology, pathophysiology, symptomatol-
ogy, and response to the therapeutic or prophylactic agents. For example, the BALB/c–L.major
model is far from being a validated model for human CL based on the above criteria. Immuno-
suppression renders BALB/c mice resistant to L.major infection [6], whereas it has the oppo-
site effect in humans. However, it is convenient, with easy read out using conventional
methods. The inbred, resistant strains have many similarities with human disease, but don’t
have the same pathological features and disease manifestations, such as secretions from the
lesions (classically known as wet lesions), chronic persistent lesions, and the variety of disease
presentation. Being inbred, these mice don’t show the variations in the presentation of the dis-
ease seen in humans; nevertheless, they are the most appropriate models available.
Ideally, outbred mice challenged by sandfly bites would be closer to human disease, particu-
larly for vaccine studies, but it would require a large number of mice with complex endpoint
evaluation (different disease manifestation) and a setup for sandfly challenge, which would be
time-consuming and expensive and also require special expertise. It is therefore not practical
for routine screening of drugs.
Many in vivo experimental models of both the NewWorld and Old World CL have been
developed for the study and testing of new compounds against the parasite, but few accurately
reproduce the biological responses that would occur in humans. Inbred mice strains are most
commonly used for experimental CL infections. However, other animal models, such as ham-
ster and rat species (primary tests), dogs (secondary tests), and nonhuman primates (tertiary
tests) have also been used. Examples of experimental CL involving dogs are lacking (though
not unheard of [7–9]), and, as a result, this paper focuses solely on rodents and nonhuman pri-
mates as the potential models for drug evaluation. In vivo models for CL should aim to mimic
the natural transmission of the disease—for example, the parasite load, presence of saliva, and
site of inoculation—to enable accurate representation of disease progression. However, in
many of the current models, this is not always the case.
The purpose of an animal model regarding CL is to investigate the parasitic cause of the
human disease and use this information in drug studies to prevent increased risk to the human
population. When exposed to the different Leishmania species, which each have individual
pathogenic characteristics, the animal model should have pathological features and immuno-
logical responses that are similar or identical to humans. The model can then be used for the
development and evaluation of new potential anti-leishmanial compounds and/or immuno-
therapy or therapeutic vaccines. There are many ethical issues that arise when using animal
models, and thus their use should be avoided when possible. The three R’s of animal testing
(Replacement, Reduction and Refinement), which were first described in 1955 by Russell and
Burch [10], must always be considered as guiding principles for the more ethical use of in vivo
models for the discovery of new drugs. The drug discovery algorithms for CL typically begin
with the in vitro high throughput screening (HTS) during lead identification, which initially
assesses the efficacy of large numbers of compounds against the parasites directly. The com-
pounds that qualify as an in vitro hit are then assessed using in silico methods to determine
their pharmacokinetic properties and toxicity during candidate identification. Assessing these
properties via computer simulation has the potential to speed the rate of discovery without the
need for expensive laboratory work. Drug discovery is a very innovative part of the drug devel-
opment pipeline, with customised in vitro HTS and in silico packages, allowing for the
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identification of drugs with high on-target efficacy, low off-target toxicity, and favourable phar-
macokinetics. Moreover, the in vitro results may potentially correlate with the in vivo studies
[11] and the in silico ADME screening tools for pharmacokinetics and pharmacodynamics are
gaining increasing accuracy and regulatory acceptance as well. Such weight is now given to
these results that drug candidates with an unacceptable in silico and/or in vitro profile are
excluded from further study by the drug developer. In vitro drug discovery has many advan-
tages over in vivo testing, such as the very quick generation of results and the minute amount
of test compound used. However, current drug screening methods in CL are laborious, espe-
cially when the intracellular amastigote model is used. In addition, the drug discovery test
results of in vitro systems will always need to be verified in animals during drug development
and before the human clinical trials of the compound begin. This is because the in vitro predic-
tions for the compounds may not necessarily transfer to in vivo situations. Similarly, results of
animal models may not be totally predictive of the response in humans, as evidenced by the
low/lack of efficacy of allopurinol alone in humans, while it was shown to be active in vitro and
in animal models [12–15].
It is also important to use recent isolates of Leishmania from the field for in vitro as well as
in vivo tests. Some laboratories prefer to use old WHO reference organisms isolated in the
1960s–1970s for consistency and uniformity; however, Leishmania change over time and those
circulating presently have different characteristics (Ana Rabello, personal communication).
Changes have also been demonstrated in L. donovani parasites kept in culture (in vitro) com-
pared to parasites freshly isolated out of rodents [16].
Nonhuman primate models are often used for the evaluation of potential anti-leishmanial
compounds as a precursor to human clinical trials [17]. However, the results achieved from
these nonhuman primate studies are often no better than those from the rodent models, and
their use over rodent models may even be inferior [18]. The determination of parasite load
within the animal model is also an important factor to consider when establishing the efficacy
of a compound.
The requirement of an animal model capable of generating reproducible results is therefore
crucial for the study of potential anti-leishmanial compounds. It is important to mention that,
as of yet, the translation of results from preclinical to clinical is very poor, hence almost no
compound has reached Phase III. With these factors in mind, it is important to determine the
most effective animal model for CL drug discovery to help focus on robust systems and reduce
the use of animals. Rodent models are most commonly used for studies of experimental CL
infections, especially when studying the pathogenesis of disease or to test novel anti-leishman-
ial agents. This is because of the high availability of cellular markers and inbred, congenic, and
now even transgenic mice, in addition to all other attributes that have made rodents a suitable
animal for laboratory-based experiments. Mice in particular are susceptible to most strains and
species of Leishmania in both the non-cure and self-cure models [19]. Much of the recent work
towards the study of CL has been based on initial findings [20–22] deducing that different
strains of mice, with differing phenotypes, vary in their susceptibility to different Leishmania
species.
Some of the observations made in the rodent models of CL might not be similar or relevant
to human hosts due to the distance in phylogeny. However, rodent models can provide a fast
turnaround during the drug research program prior to testing in nonhuman primate models.
Old World monkey species (macaques, baboons, mandrills, etc.) have the closest evolutionary
relatedness to humans among the approachable nonhuman primate models [17]. Therefore,
nonhuman primate models are generally used as the final experimental study of the safety and
efficacy of drugs, with the hope that their relatedness to humans will confer a similar mecha-
nism of CL infection and disease progression.
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003889 September 3, 2015 4 / 23
Standardization of Inoculum
It is well known that promastigotes go through developmental stages (metacyclogenesis) dur-
ing growth in culture. Therefore, the composition and size of inoculum as well as the method,
route, and site of inoculation greatly influences the outcome of infection. It is therefore impor-
tant that all these parameters are standardized for obtaining reproducible results.
During the course of in vitro growth, Leishmania undergo some essential changes (similar
to that within sandfly vector) from highly dividing but non-infective form in log phase to non-
dividing but highly infective metacyclic form in stationary phase [23]. Therefore, most labora-
tories harvest the parasite during the late stationary phase of growth and employ peanut agglu-
tinin (PNA) to remove non-metacyclic parasites before inoculation. The size of inoculum is
also important since, up to a certain level, higher doses produce larger lesions, which develop
faster. Generally, 1 × 106 metacyclic-enriched parasites were injected subcutaneously in a vol-
ume of 40μl. However, with the highly purified infective form of parasites, a few thousands of
parasites are injected to simulate delivery by infected sandflies, which are estimated to be
<5,000 [24]. The site of injection is also important for development of lesions. Footpads of
mice are usually used for drug screening and provide easy measurement of lesion and parasite
load at the lesion. The base of the tail of mice and the forehead of monkeys have also been used
for vaccine studies. Another interesting site for mouse studies is the ear, which has also been
used for inoculation by infected sandflies to simulate natural infection. Needle injections pri-
marily deliver parasites subcutaneously, whereas sandfly introduces the parasite intradermally.
The course of infections and the immune responses that ensue are different, primarily due to
the type of inflammatory cells that appear soon after the introduction of parasites at the differ-
ent sites [25]. Ideally, ear infection by infected sandflies would be preferable, particularly for
vaccine development, since it is closer to natural infection in humans and has been shown to
be different from needle challenge in vaccinated mice [24]. It should be noted that this method
should be validated for humans first before making it a prerequisite for testing safe candidate
vaccines in human clinical trials. However, this method requires availability of sandflies and
consistent maintenance of infection rates. For drug screening, needle injection of a standard
inoculum given subcutaneously in the food pad of mice would make it possible for many labo-
ratories to screen drugs, albeit not simulating natural infection.
The composition of the inoculum with respect to the types of parasites (at various stages)
should be determined and standardized. The PNA negative selection to enrich metacyclic L.
major contains apoptotic parasites that can promote infection [26] and, ideally, their propor-
tion in the inoculum should be known. The screening labs have their consistent method of
growing the parasite, harvesting at a predetermined time, and preparing metacyclic-rich inoc-
ula within their own laboratories, in order to limit variation. However, comparison of results
from different labs can be difficult because of the strain of parasite used, the age of the parasite
since the isolation from the field, method of growth, separation of infective parasite, etc.
OldWorld: L.major, L. tropica, and L. aethiopica
L. major
It is a common misconception that the BALB/c–L.majormodel is the best for studies of immu-
nology and drug evaluation regarding CL [27,28]. This misconception may be because the
method of infection is highly reproducible and thus they are widely used as an in vivo model
for CL drug discovery. Alternatively, the BALB/c–L.major has shown clinical [29] and immu-
nological features closer to the human visceral disease [30–32]. All indicate the similarity of
this model to human visceral leishmaniasis (VL) and not CL, except that a skin lesion is also
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produced. The majority of inbred mouse strains are resistant to infection by L.major (C3H/
He, CBA, C57BL/6, 129Sv/Ev [33]) and develop local cutaneous lesions, which spontaneously
resolve in 10–12 weeks. However, the BALB/c inbred strain contrasts to this and is well known
for being highly susceptible to infection. The clinical features observed in this model are quite
unlike the human disease [34] and there is much concern about its relevance, suggesting that
alternative models for drug discovery should be developed. The BALB/c mice develop large
skin ulcers, which expand and metastasize, leading to death [21]. The drug discovery algorithm
by Grogl et al., 2013, describes the concise and rigorous stages of anti-leishmanial drug discov-
ery using both the BALB/c–L.major and golden hamster–L. panamesismodels [35]. However,
the former BALB/c model has limitations when considering pathological similarities in
humans. Alternatively, the use of L.major in a humanized mouse model has proven effective
when predicting the possible side effects that may be observed in human clinical trials [36].
The L.major parasite is one of the most widely studied species in nonhuman primates. A
study in 1987 by Githure et al. described that the vervet (Chlorocebus pygerythrus), Sykes (Cer-
copithecus albogularis), and baboon species are all equally susceptible to L.major infection,
while bushbabies are resistant [37]. The vervet and Sykes monkeys, in particular, developed
erythema and conspicuous nodules on the eyelids and ears, which rapidly become ulcerating
lesions, before demonstrating a self-healing phenomenon within approximately 3 months.
This is comparable to that observed in humans infected with L.major and thus the vervet and
Sykes species are considered to be suitable models for drug trials against human CL. The L.
major parasite has also been shown to infect the vervet monkey via natural infection in the
wild [38], which enhances the model’s potential. Additionally, vervet, Sykes, and baboon spe-
cies breed fairly well in captivity [39]. One of the most ethically acceptable models for drug and
vaccine testing in nonhuman primates has been demonstrated in the L.major–rhesus monkey
(Macaca mulatta) model [40,41]. Consistent with the human cases of CL caused by L.major,
the parasite also causes a self-limiting CL of moderate severity, which resolves within three
months, suggesting that this model could serve as a prelude to human vaccine trials. However,
this model is not always feasible, given the enormous expense in conducting trials in monkeys.
The L.major–resistant strains of mice are the most appropriate available model, because of
similarities with human disease and because it is now more practical, with L.major carrying
fluorescent genes or fluorogenic markers than before with standard methods of measuring effi-
cacy. However, the L.major–rhesus model provides for evaluating immune response modifiers
(to be used for immune-chemotherapy and prophylactic vaccines) that are not active in mice,
i.e., CpG deoxyoligonucleotides with species specific sequences that can activate human and
monkey cells in vitro. These have shown therapeutic and prophylactic properties in L.major–
rhesus monkeys [42].
L. tropica
Leishmania tropica is a major cause of CL in the Middle East and some areas of Africa. Infect-
ing BALB/c mice with L. tropica results in non-ulcerating small nodules and delayed type
hypersensitivity [43]. A susceptible murine model for infection by the L. tropica strain is
needed, as there is insufficient knowledge on the pathogenicity of this parasite in mammalian
hosts, due to its difficulty to establish infection in vivo. Previous rodent models for L. tropica
infection have involved C57BL/6 and BALB/c mice [44], black rats (Rattus rattus) [45], and
Sprague Dawley rats (Rattus norvegicus spp.) [46]. None of these models effectively represent
the clinical manifestations of CL in humans. A suitable rodent model for L. tropica infection
has only recently come to light in the study by Kobets et al., 2012, which examined the genetics
and susceptibility of host response to L. tropica in BALB/c-c-STS/A (CcS/Dem) recombinant
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congenic (RC) mouse strains [47]. The CcS16 strain is more susceptible to L. tropica than
BALB/c, carrying 12.5% of genes from the resistant parental strain STS/A and 87.5% of genes
from the susceptible BALB/c strain. There is ongoing work to map the genes for susceptibility
and response to L. tropica in CcS-16 [48]. This group deduced that the response to L. tropica is
controlled by multiple genes with heterogenous effects, detecting eight loci in the CcS-16 strain
that control host–parasite interaction. The identification of these complexities will now allow
their functional basis to be elucidated and the subsequent detection of homologous processes
in humans. The CcS-16 model therefore shows great potential for the evaluation of new anti-
leishmanial drugs.
There are very few examples of nonhuman primate models infected with L. tropica. The
L. tropica infection of rhesus monkey does not follow the same immune pattern of cutaneous
infection as it usually does in humans and is not an appropriate host for the parasite [49]. Like-
wise, none of the four East African nonhuman primates studied by Githure et al., 1987, resulted
in infection after challenge with L. tropica [37]. The current nonhuman primate L. tropica
models will therefore be ineffective for drug discovery.
L. aethiopica
There are very few murine models that show susceptibility to the L. aethiopica strain and the
models that currently attempt to utilize it result in poor clinical outcomes that do not represent
the human form of the disease. The pathogenesis of L. aethiopica infection has been demon-
strated in BALB/c mice [50] whereby no ulceration of the lesion was observed and there
were no overt clinical symptoms after 203 days of infection. Likewise, Childs et al., 1984, dis-
covered that only slight swellings of the nose were seen across 12 different strains of inbred
mice infected with L. aethiopica, suggesting that murine models show little susceptibility to the
parasite [51]. The models do not represent the human form of the disease and thus are poor
models for drug discovery.
Experimental infections of L. aethiopica in nonhuman primates have not been studied re-
cently. A report by Hailu et al., 1995, evaluated the susceptibility of three species of monkey—
vervet monkey (Chlorocebus pygerythrus), Gelada baboon (Theropithecus gelada), and Olive
baboon (Papio anubis)—to the parasite [52]. Infections in all the vervet monkeys and half of
the Gelada baboons produced recognizable lesions; however, no lesions were produced during
infection in the Olive baboon. The maximum lesion size was observed among vervet monkeys
and the scars that formed after complete healing of the ulcerating lesions were typical of the
CL scars observed in humans. This species of monkey is, as of yet, the only nonhuman primate
that is susceptible to infection with L. aethiopica. However, further experimental studies are
needed to explore its potential as a nonhuman primate model of CL for the evaluation of new
drugs, due to infection with L. aethiopica.
NewWorld: L.mexicana, L. amazonensis, L. braziliensis, L.
panamensis, and L. guyanensis
L. mexicana
Most inbred mice will display susceptibility to L.mexicana and its subspecies at high doses.
However, when infected via a model that mimics natural transmission, the mice display
marked differences in their ability to control parasite growth. Of the three strains of mice
(BALB/c, C57BL/6, and CBA/J) that were subjected to a low parasite dose of 103 L.mexicana
promastigotes inoculated via the intra-dermal route of infection, BALB/c proved to be the
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most susceptible, despite all mice strains previously showing an equal susceptibility when inoc-
ulated with high dose (106) L.mexicana promastigotes subcutaneously [53].
The recent model by Sosa-Bibiano et al., 2012, made use of local mammalian fauna, the
Yucatan deer mouse (Peromyscus yucatanicus), as a model host to study the development of L.
mexicana infection with the aim of mimicking natural infection conditions [54]. The typical
human patient will develop a localized cutaneous nodular ulcerated lesion when infected by L.
mexicana, and this symptom presented itself in seven of 36 (19.44%) P. yucatanicus. Addition-
ally, the scars that resulted in P. yucatanicus were round or oval-shaped with smooth surfaces,
and showed a depression along with hypopigmentation, much like the healed lesions in
humans with CL. However, the absence of these local clinical signs was observed in 29 of the 36
animals (80.55%). Although these former results support the utility of P. yucatanicus as a novel
experimental model to study LCL caused by L.mexicana, more work is needed to utilize the
model for drug discovery.
There is no recent work on the use of L.mexicana as the parasite for infection in nonhuman
primate models.
L. amazonensis
Infection by L. amazonensismay lead to the development of diffuse CL in a few human
patients, which is characterized by nodular lesions. Recently, L. amazonensis-infected female
BALB/c mice were used to evaluate the efficacy of different CL treatments [55]. The animals
were inoculated with 107 promastigotes through subcutaneous injections at the base of the tail.
Despite some treatments showing promising results in vivo, limitations of the study included
the use of an extremely susceptible animal model and the lack of an extended period to follow
up on healing lesions. Many additional mouse strains are susceptible to L. amazonensis, in par-
ticular, the CBA strain, which develops severe lesions in comparison to C57BL/6, presenting
small chronic lesions [56]. An advantage of the C57BL/6 mouse is the large number of gene
knockout lines in the C57BL/6 background that can be used to address important questions
such as the contribution of a specific immune response to drug efficacy. In the study by Charret
et al., 2013, the CBA strain was chosen over the BALB/c strain due to its susceptibility to infec-
tion by L. amazonensis, developing cutaneous lesions without intense parasite dissemination
[18]. It was also noted from Lemos de Souza, et al., 2000, that CBA mice infected with L. ama-
zonensis produce increased levels of IL-4 and IL-10, whilst CBA mice infected with L.major
produced IFN-γ and IL-10 [57]. In humans, IL-4 is associated with disease development and
thus the similarity in immune response suggests the CBA strain has potential in replicating the
human form of CL. This CBA–L. amazonensismodel shows potential for use as a method for
the development of new anti-leishmanial drugs.
Dose-dependent lesion development was observed in both the rhesus monkey (Macaca
mulatta) and tufted capuchin (Cebus apella) infected by L. amazonensis [58,59]. Amaral et al.,
1996, infected rhesus monkeys with L. amazonensis and found that animals inoculated with
108 promastigotes consistently resulted in establishment of infection, including earlier onset
and/or larger size of lesions [58]. The cutaneous lesions of infected monkeys shared the patho-
logic features of CL in humans: amastigotes with mononuclear infiltrate of macrophages, lym-
phocytes, and plasma cells, with the formation of tuberculoid-type granulomas. However, the
DCL that could occur in humans was not observed in the animals during the time course of
experiments and it is likely that the anergic form would not have developed according to the
level of immune responsiveness found.
Garcez et al., 2002, successfully used the C. apellamonkey for experimental studies of Amer-
ican CL and as a model for vaccine trials [59]. An intermediary dose of 2 × 106 promastigotes
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was sufficient to induce consistent cutaneous lesions in these monkeys. This dose is extremely
large in comparison with the dose injected by a vector in natural infection that varies from 10
to 1,000 promastigotes [60]. However, under this high dose, all animals presented nodular
lesion development. C. apellamonkeys only developed an erythematous nodule during pri-
mary infection that varied in size and persistence, curing spontaneously, unlike humans
infected by L. amazonensis that typically developed characteristic ulcerations that do not typi-
cally self-cure. Although this L. amazonensis–C. apellamodel is considered to be a good model
for vaccine trials, it is perhaps not as good as other models (such as the L. amazonensis–rhesus
monkey), due to many aspects of infection that are dissimilar to the same disease in humans.
L. braziliensis
Less experimental work has been conducted involving the infection of rodents with L. brazi-
liensis, despite its wide distribution and burden in South America. L. braziliensis does not grow
easily in vitro [61]. Most mouse strains are resistant to infection by L. braziliensis due to the
inability of this species to inhibit the Th1 immune response [62]. Mouse strains such as C3H/
HeJ, C57BL/6J, and CBA/CaJ show no evidence of infection by L. braziliensis, whereas strains
AKR/J and CBA/J showed only a slight and transient swelling of the infected tissue, when para-
sites were inoculated in the snout [51]. Additionally, the L. braziliensis parasite has previously
been shown not to produce severe or lasting cutaneous lesions in the BALB/c mouse strain
[20], which has even been shown to kill the L. braziliensis parasite after infection and is there-
fore highly resistant [62]. However, a few reports have employed a BALB/c model in vaccina-
tion studies that successfully obtained chronic ulcerated lesions after infection by L. braziliensis
promastigotes [63,64]. The addition of salivary gland exudates promotes infection in mice due
to the presence of highly active vasodilators. Some of these proteins (LJM11) are now being
used to generate blocking antibodies/cellular response in vaccine studies to reduce infection
and lesion formation [65].
The only model which shows true potential for the evaluation of potential drugs targeting L.
braziliensis is the golden hamster (Mesocricetus auratus). Hamsters are commonly used for
strains of Leishmania that show low susceptibility to mice (L. Viannia subspecies), and disease
progression can be monitored over longer periods of time due to the chronic nature of the dis-
ease in the rodent [14]. Gomes-Silva et al., 2013, demonstrated that, after infection with L. bra-
ziliensis, all hamsters developed cutaneous lesions very similar to those observed in humans
during the observational period (110 days), with no spontaneous healing [66]. Although this
particular hamster model shows predictable disease evolution, other models using different iso-
lates and/or protocols have not shown reproducibility, especially in contrast to other well-
established mouse/Leishmaniamodels such as the BALB/c–L.majormodel. Nonetheless, the
golden hamster could be recommended for clinical vaccine or therapeutic studies against L.
braziliensis due to the fact that the chronic state of the disease closely resembles non-healing
human CL and possibly reproduces some of the immunopathological aspects of the human dis-
ease. Unfortunately, the wider use of hamsters is still limited for CL drug discovery due to the
lack of available reagents—such as antibodies to cell markers and cytokines specific to the CL
response [67]—in addition to the higher doses of drugs required to dose hamsters compared to
mice.
The L. braziliensis–rhesus model induced self-healing CL in which the T cell-mediated
inflammatory response effectively promoted parasite clearance and granuloma resolution, with
the lesional granulomas being remarkably similar to those seen in humans infected with the L.
braziliensis pathogen [68]. A similar study by de-Campos et al., 2010, also confirms that the
model can be used to elucidate the regulatory mechanisms that may render granulomas
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inadequate for fighting intracellular pathogens [69]. Further study of the various immune sup-
pression mechanisms that induce granulomas in L. braziliensis-infected rhesus monkeys may
reveal new opportunities for therapeutic control of the disease. The marmoset (Callithrix peni-
cillata) has also been shown to develop a cutaneous lesion at the point of inoculation by L. bra-
ziliensis [70]. In this experiment, all but three of the 14 marmosets developed this lesion three
to nine weeks after infection, and were characterized by the appearance of subcutaneous nod-
ules containing parasites. The model may serve as a useful experimental model for the study of
CL in the future, but for now, further work is needed.
L. panamensis
The initial study by Neal and Hale, 1983, demonstrated that the BALB/c mouse strain is sus-
ceptible to high inoculums of L. panamensis promastigotes [20]. Subsequent work by Castilho
et al., 2010, utilized this knowledge to develop a chronic infection model for L. panamensis
using numbers of parasites that would more closely approximate infection in nature [71].
5 × 104 L. panamensis promastigotes generated chronic lesions in BALB/c mice with persistent
parasites at the site of the infection for over one year. They also discovered that the immune
response of the mouse resembles that found for L. panamensis-infected patients with chronic
and recurrent lesions. Thus, the murine model should be useful in the understanding of the
pathology of the human disease and may eventually be used as a model to develop methods for
the treatment and prevention of CL caused by L. panamensis parasites. The golden hamster has
also been shown to be susceptible to L. panamensis infection [72] but the cutaneous metastatic
lesions vary considerably between animals and thus the model is unreliable. There is little
research into L. panamesis-infected nonhuman primate models, however, one early study was
reported using aotus monkey for evaluation of allopurinol [13].
L. guyanensis
There are very few examples of L. guyanensis–rodent animal models. However, the golden
hamster has been shown to provide an experimental model for most L. Viannia species, includ-
ing L. guyanensis [72,73]. The extent of the model’s usefulness is limited, however, and not rep-
resentative of the human disease. Very little research has been conducted into L. guyanensis–
nonhuman primate models of infection and hence their use for the evaluation of potential anti-
leishmanial compounds remains unclear.
It is important to note that there are many experimental variables that can be used to modu-
late disease outcome. These variables involve methods in the administration of the disease and
affect phenotypes, such as modular or ulcerative lesions and fast or slow development of dis-
ease. These variables, including parasite dose [74], site of inoculation [75], co-injection with
sandfly saliva [76], and temperature [77], have all been shown to affect disease outcome in ani-
mal models, thus demonstrating the importance of mimicking the natural route of infection in
all animal models.
Continuous Monitoring of the Parasite Load in the In Vivo Models,
Using Reporter Molecules
Leishmaniasis affects many millions of people worldwide and hence there is an ever-growing
need for a rapid screening assay to allow the high throughput screening of potential anti-leish-
manial compounds. The current classical methods of in vivo parasite load determination are
laborious, time consuming, and do no support automation. Furthermore, methods such as
lesion size measurements are not always indicative of parasite killing due to immunological
responses such as inflammation, which might also contribute to lesion size. Previously,
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methods required the animals to be euthanized at various times after infection. Quantification
was then achieved by measuring the parasite load either by microscopy, limiting dilution assay,
or q-PCR amplification of the parasite DNA. As Calvo-Alvarez et al. wrote, “Furthermore, this
approach has some important limitations that must be overcome: (i) postmortem analysis of
animals makes it impossible to track the space/time progression of the pathogen within the
hosts; (ii) spread of the pathogen to unexpected anatomic sites can remain undetected; (iii) in
order to achieve precise and relevant data, it is necessary to kill large numbers of animals” [78].
The measurements of lesion size and footpad and ear thickness are all common methods used
to quantify the progression of the disease and hence the parasite number [35,66]. However,
these methods require an incubation period of about two weeks before any visual observations
of infection can be made. Thus, it is important to devise a way of detecting parasite numbers in
the earlier stages of infection, before a visual phenotype is observed. More recently, the in vivo
imaging system (IVIS) has been developed to allow the detection of measurable signals associ-
ated with cells in living organisms [79]. It is extremely important to quantify the parasite load
present in an in vivo model in a live host, in order to determine the infectivity of the Leish-
mania parasite and/or to measure the efficacy of a potential anti-leishmanial drug.
Many reporter molecules have been devised for the quantification of protozoan parasites
and each one comes with different degrees of sensitivity, advantages, and disadvantages.
Reporter genes must encode a gene product that has a readily measurable phenotype that must
also be distinguishable over a phenotypic background [80]. As described by Dube et al., 2009,
“The ideal reporter gene should be (i) absent from the host; (ii) inert (and should not affect the
physiology of the parasite cell); and (iii) should represent a simple, sensitive and inexpensive
assay for quantification of reporter expression” [81]. Continuous monitoring of parasite load
in vivo is an ideal way to monitor drug treatment outcome.
β-galactosidase
β-galactosidase is widely used as an intracellular reporter gene and is the product of the bacte-
rial lacZ gene. The primary advantages of using β-gal as a reporter gene is its simplicity, low
cost and sensitivity. Depending on the substrate used, it offers a number of detection options
[81]. The reporter molecule cannot be applied directly in vivo to observe the parasite load and
progression in real time analyses, but β-galactosidase-positive L. amazonensis parasites were
easily detected in mouse tissue as blue spots after staining with X-Gal [82]. Nevertheless, a con-
siderable drawback to this method is the large size of the β-gal-expressed protein (116kDa) and
its endogenous expression within most mammalian cell lines (macrophages), resulting in a
false positive readout for parasite growth [81]. For this reason, the molecule is inaccurate for
the quantification of parasite load, especially when determining the efficacy of a potential drug.
β-lactamase
Unlike β-galactosidase, the reporter molecule β-lactamase shows no endogenous expression by
mammalian cells and hence proves to be an excellent choice for protozoan reporter gene assays
[83,84]. Betalactamases are a family of bacterial enzymes that cleave penicillins and cephalo-
sporins [81]. The method is rapid, sensitive, and nonradioactive. Bukner and Wilson, 2005,
engineered strains of L.major and L. amazonensis expressing the β-lactamase gene in an
episomal vector [83]. Their method facilitated the relatively high throughput screening of the
intracellular stages of the Leishmania strains against chemical libraries with potential anti-
leishmanial activity. However, its utility was still limited as it was necessary to keep strong
selective pressure over the parasite in culture to avoid the possible elimination of the parasite’s
episomal construct. This colorimetric assay also requires the lysis of cells, and repeated
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measurements are not always possible. The β-lactamase reporter gene system devised by Man-
dal et al., 2009, uses transgenic parasites to optimize their utility in amastigote–macrophage
drug screening assays, and is a vast improvement of the 2005 Buckner andWilson model [84].
Currently, the β-lactamase reporter gene has not been applied directly in vivo.
Luciferase
The gene expressing luciferase has been cloned from several different species, the firefly lucifer-
ase being the most commonly used form. Luciferase catalyses the oxidation of luciferin in the
presence of Mg2+ and ATP into oxyluciferin, which produces a short flash of light directly pro-
portional to the number of luciferase enzyme molecules. Thus, it provides a rapid indication of
the transcriptional activity of the gene [81]. Roy et al., 2000, was able to visualise transfectant L.
major strains stably expressing the firefly luciferase gene in vivo to monitor disease progression
in real time analyses [85]. Likewise, a recent paper by Thalhofer et al., 2010, describes the IVIS
technology which enabled the noninvasive visualization of luciferase-expressing Leishmania
spp. parasites in living anesthetized BALB/c mice in real-time [79]. This technique allowed
bio-imaging at the highest efficiency with the absence of background activity by host cells. A
similar study was conducted by Lang et al., 2005 [86]. The IVIS technique has also been utilized
to assess drug therapy (amphotericin B) on L. amazonensis infection in the skin of BALB/c
mice [87]. This model enabled successful visualization of the decrease in parasite load after
treatment with AmB in the mouse model. However, the method also comes with its disadvan-
tages. The methodology is limited by the requirement of the substrate luciferin, which must be
administered intravenously or intraperitoneally for the detection of the luciferase activity. This
makes the technique expensive [81]. Additionally, the luminescence produced is unstable and
dependent upon the metabolic activity of the cells, which have been transfected with luciferase.
Green Fluorescent Protein
All of the above mentioned reporter genes require exogenous substrates, which limit their use
and introduce an extra step in the detection of reporter expression. Using fluorescence for
determining parasite load has many advantages over other reporter molecules. The fluorescent
proteins work intrinsically, which allows real-time analysis of the molecular events in living
cells. Additionally, fluorescent reporters do not require specific substrates and the fluorescence
emitted is very stable over time. The use of fluorescence allows greater simplicity, easier kinetic
monitoring, low cost, and enhanced biosafety [88], and thus has great potential for in vitro
HTS of potential drug candidates. Green Fluorescent Protein (GFP) is the most commonly
used fluorescent reporter molecule. It has been used over a large number of species for in vitro
drug screening due to its flexibility, sensitivity, and the additional possibility of automization of
the screening process using flow cytometry or fluorometry [88]. Variants of the GFP have been
developed, which have optimal properties for high-throughput screening. These variants have
different emission spectra and can fluoresce at wavelengths longer than that of native GFP, as
seen in the enhanced green fluorescent protein (EGFP) [89]. More recently, the stable transfec-
tion of the EGFP reporter has been found suitable for in vivo as well as in vitro infection stud-
ies, showing potential use in drug screening assays in vivo, as there are no considerable
variations in virulence or infectivity due to the genetic manipulation of the parasites [89,90].
Infrared fluorescence has recently been utilised as a tool for in vitro, ex vivo, and in vivo models
of visceral leishmaniasis [91]. Here, in vivo noninvasive imaging of the visceral infection in
BALB/c mice was achieved using transgenic fluorescent parasites. It is possible that this
method may be transferred to studies of CL, opening up the possibility of testing vast amounts
of potential drug compounds.
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The introduction of the fluorescent reporter gene into the Leishmania parasite can be either
transgenic or episomal. The use of an episomal vector carrying a given gene is limited for two
reasons: (1) Gene expression is extremely heterogeneous in populations of transfected parasites
due to the wide variation in the copy number of plasmids per cell. (2) The host loses the plas-
mid in the absence of an antibiotic resistance marker. These problems can be overcome by the
integration of the reporter DNA into the parasite genome, thus creating a permanent transfec-
tant [92]. Expression of GFP as an episomal transgene is useful for drug screening in either
promastigotes or intracellular amastigotes in vitro (by flow cytometry [93]) and in vivo [94],
but fluorescence in those parasites was very heterogeneous due to variation in the number of
copies of the transgene. For the reasons described, it is more practical to consider transgenically
introduced reporter genes in order to efficiently determine the parasite load. The GFP reporter
system still has its disadvantages. The excitation maximum is close to ultraviolet (UV) range,
which can cause damage to living cells. Additionally, the GFP model is not sensitive enough to
enable a precise and reliable microplate screening in vitro, and, consequently, an in-depth flow
cytometric analysis is required.
EGFP-labelled L.major transfectants have been detected in both the amastigote and pro-
mastigote stages in the footpad lesions of BALB/c mice [89]. The study showed an in vivo cor-
relation between parasite fluorescence and footpad thickness, suggesting that the method could
be applied as a semi-quantitative parameter for parasite load. The paper also suggests that the
model could be utilized for in vivo real-time whole body fluorescence imaging and eventually
be applied to different animal species such as hamsters and dogs. Pulido et al., 2012, used Bol-
hassini’s system to describe the first NewWorld Leishmania strain (L. panamensis) to stably
express GFP transgenically [90]. Their in vivo model uses the golden hamster, which they
described as the best animal model for CL (based on work by Hommel et al., 1995 [95]),
infected with L. panamensis plR3(-)eGFP. Fluorescence was homogenous and persisted for
long periods of time. Promastigotes taken from the infected hamster were used to infect and
produce induration in the hamster nose, indicating that the virulence of recombinant strains is
not affected by genetic manipulation. Transfected cells remained as a homogenous and unique
population.
A recent paper by Calvo-Alvarez et al., 2012, suggests that fluorescent reporter molecules
that emit light in the red spectrum prove excellent candidates for in vivo drug screening assays
[78]. The group used mCherry as their red reporter molecule, which was considered the best
choice for their studies based on improved photostability and suitability for intravital imaging.
The transgenic L.major LV39c5 + mCherry strain was used to infect BALB/c mice. Lesion size
and fluorescence intensity showed good correlation. As the authors wrote, “It is remarkable
that a weak but measurable fluorescence signal from infected hind limbs was detectable two
weeks prior to visible and measurable injury took place in all dose groups” [78], and the in vivo
model was subsequently applied to a vaccination study. Fluorescence was lower in the vacci-
nated group than the control by 80%. These results were reproducible, thus indicating that the
model can be considered a highly suitable system for drug discovery. The mCherry fluorescent
protein system is highly sensitive—being able to detect 104 amastigotes isolated from a lesion—
and shows possibilities for automation and miniaturization, reducing both cost and time.
Another recent paper utilises two reporter proteins: EGFP and luciferase combined [96].
They generated stable transgenic L.major expressing fused EGFP and firefly luciferase simulta-
neously, thus increasing the experimental sensitivity. These signals from the parasite were mea-
surable within a mammalian host (BALB/c mice) and promastigotes. Their results concluded
that both quantitative reporter genes could be used to detect parasite load in vitro and in vivo
and demonstrated that firefly luciferase was 10-fold more sensitive than EGFP in promastigote
stage. This model also has exciting potential for use in drug discovery.
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Discussion
To summarize, animal models that show the greatest potential for the evaluation of new poten-
tial anti-leishmanial drugs have not been certified, and this review goes some way in clarifying
our understanding of the predictive validity and representativeness of the models for human
disease. Currently, the BALB/c–L.majormodel is one of the most widely used. The idea of
using BALB/c mice for drug studies is based on the notion that if the BALB/c mice can be pro-
tected or cured from the parasite disease, then so can the resistant mouse strains. However,
using this model will possibly result in the inability to detect potentially useful compounds due
to the stringencies and peculiarities associated with it. The risk of overlooking such compounds
is too great, and thus, the model has limitations. Despite this, it should be noted that the choice
of a rodent model strongly depends on the research question that is being addressed. The use
of BALB/c–L.major can be justified in drug testing, as it is reproducible and generally accepted
to be a rigorous test. CL progresses quickly in this non-healing model; hence, when a lesion
size and parasite load reduction is obtained, it is likely to lead to reduction in other self-cure
models. The in vivo model should be considered solely as a predictive tool in a complete set of
experiments involving in vitro and additional in vivo work in which each experiment answers
a different defined question, as demonstrated by Grogl et al., 2013.
It is usually difficult to refute a dogma. The BALB/c–L.majormodel has been used for test-
ing drugs for decades [97,98], primarily because of extreme sensitivity of BALB/c to L.major
infection and ease of outcome evaluation. It is now clear that the outcome of the infection is
directly influenced by the immune responses of the host. It is also known that L.major infec-
tion in BALB/c triggers a strong Th-2 response to leishmanial antigens, leading to rapid lesion
growth and generalized infection and, eventually, death. Hence, as mentioned elsewhere in the
text, immune-suppressive agents, which control this Th-2 response, reduce the lesion size and
parasite load. We would like to caution that reduction in lesion size and parasite burden may
not be due only to the anti-parasitic activity of the agents being tested but also their effects on
the immune responses. As of yet, the most comprehensive rodent models are the L. tropica–
CsS-16 [48], L. amazonensis–CBA [18], and L. braziliensis–golden hamster [66], which each
show promise for drug discovery (Table 1).
Many Leishmania species are ineffective at producing human-like immune and clinical
responses in nonhuman primate models, or else have not been widely studied (L. tropica, L.
mexicana, L. panamensis, and L. guyanensis). The L.major–vervets model is one that well rep-
resents the human form of disease and has the additional advantage of the animal breeding rel-
atively well in captivity. The vervet monkey has also been shown to produce recognizable
lesions after infection with L. aethiopica, but more research is needed to evaluate the models’
potential for drug discovery. The L.major–rhesus model also shows consistency with human
cases of CL and has been used in vaccine evaluation. Both the rhesus monkey and Cepus apella
develop clinical symptoms after infection with L. amazonensis, however, the former model is
more representative of the human CL disease and thus may be better for drug trials. The rhesus
monkey also develops characteristic lesional granulomas remarkably similar to those seen in
humans infected with L. braziliensis. Therefore, the L.major–vervets (37), L.major–rhesus
[40,41], and L. braziliensis–rhesus [68,69] models show the greatest potential for the evaluation
of new potential anti-leishmanial drugs.
The use of nonhuman primate models for the evaluation of potential anti-leishmanial com-
pounds is often used as a precursor to human clinical trials. However, the results achieved
from these nonhuman primate studies are often inferior to those that use rodent models. Non-
human primates should only be used as a model for drug evaluation if rodent models are inca-
pable of reproducing reliable results. As of January 1, 2013, Directive 2010/63/EU replaced
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Directive 86/609, stating that the use of nonhuman primates can only be used under strict cir-
cumstances, for example, for the benefit of human beings when it involves life-threatening or
debilitating diseases. Nonhuman primates must only be used if there is scientific justification
to the effect that the purpose of the procedure cannot be achieved by the use of species other
than nonhuman primates. Their use should not be sanctioned during the early stages of
research and is more appropriate for toxicology testing at the preclinical stage of development.
Often, the rodent models are far better at assessing the efficacy of a drug, and some reproduce
aspects of human infection to a far greater extent than the nonhuman primates. When consid-
ering in vivo models for drug discovery purposes, it should be noted that only small fractions
of drugs are available. Relatively restricted amounts of drug are used in mice, being smaller
than hamsters. Nonhuman primate models require much higher doses that are often not avail-
able at early stages. Animal models that show potential for studies of drug evaluation should
have obtained the disease through a method that mimics natural infection and, additionally,
should present similar clinical symptoms as are observed in humans. It is also important to
choose the right animal model for the Leishmania species, since it has been demonstrated in
multiple clinical trials that the efficacy of a given compound varies depending on the species of
Leishmania causing the infection. These factors should be considered although it is acknowl-
edged that such parameters are not always feasible. From this analysis, we conclude that L.
major–vervet, L.major–rhesus, L. tropica–CsS-16, L. amazonensis–CBA, L. braziliensis–
golden, or L. braziliensis–rhesus are the best models for CL drug discovery. However, the use of
these nonhuman primate models should only be used under extreme cases whereby they con-
form to the new directive and are scientifically justified.
Neither β-galactosidase nor β-lactamase are effective reporter molecules for in vivo drug
discovery. However, their use in vitro is widely used due to their simplicity and low cost. The
use of the firefly luciferase reporter molecule in transgenic Leishmania species shows exciting
results in its use for drug evaluation due to its high sensitivity and use in real-time analyses;
however, the process is costly due to the need for the substrate luciferin. Alternatively, fluores-
cent reporter molecules can be used to determine parasite load and have the advantage that
they do not require the use of exogenous substrates. Fluorescent proteins work intrinsically,
allowing for the real-time analysis of the molecular events in living cells. Although the GFP
and its variants have been used to quantify Leishmania parasites in in vivo models previously,
there are concerns that the excitation maxima of these proteins are close to the UV range, caus-
ing damage to living cells. The recent mCherry + L.majormodel has been shown effective in a
vaccination study in BALB/c mice and has greater sensitivity over the more commonly used
GFP models. Additionally, the combined use of EGFP and firefly luciferase in the L.major–
BALB/c model demonstrates a highly sensitive method for parasite quantification that has
potential for drug evaluation.
It is important to emphasize the extra valuable information we can obtain using reporter
molecules as tools for calculation of parasite load when compared to conventional methods.
The conventional methods used to quantify parasite load, such as the direct measurement of
parasite via microscopy or q-PCR amplification of parasite DNA, are not only laborious and
time consuming, but also require the euthanasia of large numbers of animals. In addition, these
methods cannot detect the spread of pathogens to unexpected anatomic sites or track their
space/time progression. In contrast, reporter molecules provide a readily measurable pheno-
type that allows the continuous monitoring of parasite load in vivo. These tools are highly sen-
sitive and often show potential for automation resulting in high-throughput quantification,
especially when combined with computational methods.
Current animal models for the utility and discovery of new potential anti-leishmanial drugs
differ vastly in their immunological response to disease and clinical presentation of symptoms.
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After the initial HTS of the drugs in vitro, animal models are used to ensure correlation of drug
results in vivo before human clinical trials begin. Infected animal models with similarities to
the human form of CL should be more representative when considering the effectiveness of a
compound within a human. Models with dissimilar clinical presentations should be avoided.
The accurate quantification of parasite load and, thus, effect of a drug must then be determined
through the use of reliable quantification methods as described. It should also be noted that the
overall curative effects of anti-leishmanial drugs in vivo depend not only on antiparasitic activi-
ties of the agents but also on immune responses of the host. Hence, understanding the immu-
nopathology of the animal model is important when selecting agents for clinical development.
In conclusion, we found that the following models are the most suitable for the assessment
of anti-leishmanial drugs: L.major–C57BL/6 mice or–vervet monkey, L.major–rhesus, L. tro-
pica–CsS-16, L. amazonensis–CBA, L. braziliensis–golden or L. braziliensis–rhesus. We also
found that the other models investigated here are not currently supported. The guidance pro-
vided in this report should help when considering a CL animal model for drug discovery, and
we suggest that further work should focus on these recommended models.
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Key Learning Points
• It is important to choose the right animal model for the Leishmania species, since it
has been demonstrated in multiple clinical trials that the efficacy of a given compound
varies depending on the species of Leishmania causing the infection.
• In many cases, rodent models are far better at assessing the efficacy of a drug, and
some reproduce aspects of human infection to a far greater extent than nonhuman
primates.
• Quantification of the parasite load present in an in vivo model is important to deter-
mine the infectivity of the Leishmania parasite and/or to measure the efficacy of a
potential anti-leishmanial drug.
• We conclude that L.major–vervet (or–rhesus), L. tropica–CsS-16, L. amazonensis–
CBA, and L. braziliensis–golden (or–rhesus) are the best models for CL drug discovery.
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